FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML
CICLOSPORINMYCOPHENOLATE MOFETILFludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusionCYCLOPHOSPHAMIDETrecondi 5 g powder for solution for infusion
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death
Endpoint detail
Conditioning related toxicity according to CTCAE, rate of graft failure, Cumulative incidence of neutrophil and platelet recovery, Cumulative incidence of acute GVHD, Cumulative incidence of chronic GVHD, Cumulative incidence of NRM, Probability of Overall Survival, Probability of GVHD, Prevalence of immunosuppressive therapy (IST) and GVHD at 3, 6, 9, 12 months
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.